Quarterly report · Q2
3151.TEDINET S100PL90
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥289.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥577.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥285.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥730m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥934m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥316.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥313.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥327.3bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥212.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥213.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥103.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥100.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥105.6bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥27.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥23.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.4bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥27.42 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.4 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.88 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.67 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.01 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.4% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.0% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥146m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥6.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥6.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥58m |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥278.2bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥273.0bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥607m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥32m |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥178m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥292.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥287.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥819m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥295.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥289.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥672m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥3.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | −¥97m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥5.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥5.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | ¥19m |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥273.4bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥269.1bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥739m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥83m |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥189m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥287.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥283.3bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.3bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥290.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥285.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥915m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 433000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 408000000 | JPY |
| Office work fee received ope cf | Prior1YTDDuration | 742000000 | JPY |
| Office work fee received ope cf | CurrentYTDDuration | 784000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -49000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -51000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -286000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -2255000000 | JPY |
| Income taxes refund ope cf | Prior1YTDDuration | 1156000000 | JPY |
| Income taxes refund ope cf | CurrentYTDDuration | 857000000 | JPY |
| Other net ope cf subtotal | Prior1YTDDuration | 4000000 | JPY |
| Other net ope cf subtotal | CurrentYTDDuration | 5000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 5557000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 4035000000 | JPY |
| Net decrease increase in time deposits inv cf | Prior1YTDDuration | -200000000 | JPY |
| Net decrease increase in time deposits inv cf | CurrentYTDDuration | -150000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -2328000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -1108000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | 199000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | 102000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -190000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -306000000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -177000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -183000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | 265000000 | JPY |
| Payments of loans receivable inv cf | Prior1YTDDuration | -10000000 | JPY |
| Payments of loans receivable inv cf | CurrentYTDDuration | -60000000 | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 19000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 25000000 | JPY |
| Proceeds from redemption of investment securities inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from redemption of investment securities inv cf | CurrentYTDDuration | 100000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | -217000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | － | JPY |
| Other net inv cf | Prior1YTDDuration | 133000000 | JPY |
| Other net inv cf | CurrentYTDDuration | 113000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -2772000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -1200000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | -130000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -485000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -485000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -321000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -379000000 | JPY |
| Proceeds from disposal of treasury stock fin cf | Prior1YTDDuration | 3000000 | JPY |
| Proceeds from disposal of treasury stock fin cf | CurrentYTDDuration | － | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -712000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -998000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -0 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -745000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |